What is NSRX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for NSRX.

Stock Ratings / Health Care / NSRX / options

GRDX (39) EDSA (29) VERU (30) SCYX (28) ⌘ Pro Terminal →

Nasus Pharma Ltd. (NSRX) Options Positioning, Max Pain & Unusual Sweeps

$3.20 +4.21% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.22

Nasus Pharma Ltd. (NSRX) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $36.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NSRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NSRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Nasus Pharma Ltd. (NYSE: NSRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $3.20 (+4.21% 1D, market cap $36.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NSRX ranks #914 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NSRX compare to GRDX and EDSA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NSRX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GRDX (GridAI Technologies Corp.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -20.0%, cap $35.4M) and EDSA (Edesa Biotech Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $34.7M). Among the 5-stock peer group, NSRX leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NSRX?

▼

Per NSRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002029039), Nasus Pharma Ltd. generated $1.24B in revenue (+40815.7% YoY), -$5.9M in net income, and -$4.9M in free cash flow against $5.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.22 (+0.57%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NSRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY NSRX SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.16+2.5% Next Q

Q2 (-2Q)

Grade E$3.24+2.5% Next Q

Q3 (-1Q)

Grade E$3.32-3.6% Next Q

Current

Grade E$3.20-10.5% Hist 90D α

Trajectory: E (18) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NSRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NSRX currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.54) and Max Pain ($3.36) forces dealer call-delta covering toward $9.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NSRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NSRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NSRX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NSRX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NSRX)

✓Walkthrough of NSRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NSRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.52%▲ ASCENDING TRIANGLE

2026-11-03O $3.19H $3.20L $3.07C $3.20VOL 4.9K

RES: $4.10SUP: $3.05SMA50: $3.54SMA200: $3.60

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NSRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NSRX Butterfly Map → + Track NSRX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +40815.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NSRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NSRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NSRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NSRX)

Health Care Rank #914 of 1015 ⚔️ GRDX vs NSRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NSRX vs. GRDX, EDSA, VERU, SCYX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nasus Pharma Ltd. (NSRX) ranks #914 by composite RQD confidence (26/100, grade E) and #780 by equity capitalization ($36.0M). Within this direct 5-issuer industry benchmark cohort, NSRX leads on earnings valuation at N/A trailing P/E, while GRDX leads on capital efficiency and profitability with -20.0% ROIC and -30.0% gross margin. GRDX currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with NSRX at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NSRX ACTIVE Nasus Pharma Ltd.	E	26/100	—	—	-35.0%	+4.21%	$36.0M	Benchmark Subject
GRDX GridAI Technologies Corp.	D-	39/100	—	-30.0%	-20.0%	-3.43%	$35.4M	/grdx-vs-nsrx →
EDSA Edesa Biotech Inc.	E	29/100	—	—	-35.0%	-5.06%	$34.7M	/edsa-vs-nsrx →
VERU Veru Inc.	E	30/100	—	—	-35.0%	-1.37%	$37.3M	/veru-vs-nsrx →
SCYX SCYNEXIS Inc.	E	28/100	—	—	-35.0%	+1.06%	$37.5M	/scyx-vs-nsrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002029039 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nasus Pharma Ltd. (NSRX) reported GAAP revenue of $1.24B (+40815.7% vs. FY2024 revenue of $3.0M , and +38354.4% cumulative change since FY2023) , GAAP net income of -$5.9M, operating cash flow of -$4.9M, and free cash flow of -$4.9M (-641.7% YoY). On the balance sheet, NSRX closed FY2025 with $5.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.24B	-$5.9M	-$4.9M	-$4.9M	$5.0M	—
FY2024 (FY)	2024-12-31	$3.0M	-$1.5M	-$665.0K	-$665.0K	$717.0K	—
FY2023 (FY)	2023-12-31	$3.2M	-$1.1M	-$1.0M	-$1.0M	—	—

3. NSRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NSRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NSRX compare to GRDX and EDSA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NSRX?

Where is NSRX trading relative to its 50-day, 200-day, and 52-week technical levels?

NSRX last traded at $3.20 (+4.21% on volume of 4,751 shares), positioning the stock -9.60% below its 50-day simple moving average ($3.54) and -11.11% below its 200-day simple moving average ($3.60). Across its 52-week range of $1.98 to $9.50, NSRX sits at the 16.2% percentile with a 14-day RSI of 39.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.80 to $3.60).

Direct Sub-Reports: NSRX RQD Cockpit NSRX 12M Forecast NSRX Earnings & Move NSRX Dividends & DRIP NSRX Insiders & 13F NSRX Whale Options NSRX Profit Sankey NSRX News & Why

ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

NSRX — Nasus Pharma Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nasus Pharma Ltd. (NSRX) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.20 (+4.21% 1D, market capitalization $36.0M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -0.4%, and free cash flow yield of -13.20%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nasus Pharma Ltd. (NSRX) is a NYSE-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $36.0M. The business operates with a gross margin of 0%, an operating margin of -0.4%, and a return on invested capital (ROIC) of -35% (free cash flow yield of -13.2%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nasus Pharma Ltd. (NSRX) reported $1.24B in annual revenue (up from $3.0M in FY2024, +40815.7% YoY) and -$5.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.2M revenue, -$1.1M net income) through FY2025, NSRX scaled operating cash flow to -$4.9M and free cash flow to -$4.9M, backed by $5.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -13.20% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.98 – $9.50 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -0.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links and no proprietary signals are recorded. Supply-chain dependencies are therefore — Sector correlations beyond the stated Health Care sector classification are — Investors should monitor any future disclosure of supplier, partner, or customer concentration, as the source data cannot establish second-order bottlenecks.

Key Question #1: Can NSRX sustain or expand its -0.4% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.24B and free cash flow of -$4.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NSRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NSRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nasus Pharma Ltd. (NSRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NSRX Debate Forum (3) ↓

🟡 MARKET WIRE GuruFocus • 1d ago

NSRX Initiates Coverage On by Maxim Group -- Rating Set to Buy

GuruFocus report covering Nasus Pharma Ltd. (NSRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Maxim Group initiates coverage of Nasus Pharma at Buy, sets price target at $7

TradingView report covering Nasus Pharma Ltd. (NSRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 1d ago

This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Benzinga report covering Nasus Pharma Ltd. (NSRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.dars.gov.et • 1d ago

Nasus Pharma (NSRX) Slips 2.69% to $3.25 as Shares Test Lower Support Zone - Strong Buy Stocks

www.dars.gov.et report covering Nasus Pharma Ltd. (NSRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Nasus Pharma (NSRX) Jumps 8.05% to $3.49 as Shares Press Toward Upper Trading Range - Keltner Channel

https://www.siam.in/ report covering Nasus Pharma Ltd. (NSRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 2d ago

Nasus (NSRX) Charges Higher by +2.75%, Clearing $4.12 2026-10-04 - Call Wall

https://www.siam.in/ report covering Nasus Pharma Ltd. (NSRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 2d ago

Is Nasus (NSRX) Still a Buy After +8.05% Rally? 2026-10-26 - Max Pain Level

https://www.dars.gov.et/ report covering Nasus Pharma Ltd. (NSRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 2d ago

Nasus Pharma Ltd. Stock Price Prediction: Today, Tomorrow, Next Week (NSRX)

Traders Union report covering Nasus Pharma Ltd. (NSRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NSRX Bull vs. Bear Conversation Board — What's Your Call at $3.20?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NSRX 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $4.02 (+30.9%)

📌 Pinned Debate

A Maxim Group initiation at Buy with a $7 price target sits well above the current $3.19 share price.

Don't sleep on NSRX's setup in Health Care. A Maxim Group initiation at Buy with a $7 price target sits well above the current $3.19 share price.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (26/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $2.61 (-15.0%)

Spot @ $3.07

Negative ROIC of -35% and FCF yield of -13.2% alongside an RQD score of 27 signal weak cash generation and forensic risk.

Fading this rally in NSRX at $3.07. Negative ROIC of -35% and FCF yield of -13.2% alongside an RQD score of 27 signal weak cash generation and forensic risk.. With a beta of 1.0 and the stock sitting at $3.07 (52-wk range $1.98–$9.50), the easy multiple expansion is already priced in.